- A propritary drug reprofiling strategy to identify new uses for 'safe' drugs to treat human immune system diseases e.g. inflammation, haematological cancers (leukaemias and lymphomas), allergy, autoimmune disease and graft rejection.
Celentyx allows access to NCIP™ through it's NCIP™ partnering.